Videos

Edward Bradley, MD, gives an overview of the mechanism of action and development of moxetumomab pasudotox, a monoclonal antibody directed at CD22.

Julian Adams, PhD, President, Research and Development, Infinity Pharmaceuticals, describes a phase I trial of IPI-145, a potent inhibitor of PI3KEδ and PI3K-γ.

Richard L. Schilsky, MD, from University of Chicago Comprehensive Cancer Center, explains the benefit to generic drug user fees.

Richard Finn, MD, comments on the future of palbociclib (PD 0332991), a novel oral selective inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6), for the treatment of breast cancer.

Sandra Swain, MD, from the Washington Cancer Institute at MedStar Washington Hospital Center, on the practice-changing information from the 2013 ASCO Meeting.

Antoni Ribas, MD, PhD, comments on the efficacy of lambrolizumab, an anti-PD-1 antibody, in patients with advanced melanoma.

Andrew T. Parsa MD, PhD, describes the development and trial involving prophage G-200, a vaccine for recurrent glioblastoma multiforme.

Marcia Brose, MD, PhD, discusses the rationale, background, and results from the phase III DECISION study that explored sorafenib in radioactive iodine-resistant differentiated thyroid cancer.

Richard Pazdur, MD, from the FDA’s Center for Drug Evaluation and Research, describes the benefits of a Breakthrough Therapy Designation.

Roy S. Herbst, MD, PhD, comments on the emergence of immunotherapies for multiple types of cancer including MPDL3280A for non-small cell lung cancer.

Clifford A. Hudis, MD, Attending Physician, Memorial Sloan-Kettering Cancer Center, discusses his optimism surrounding immunotherapy for cancer care.

Krishnansu S. Tewari, MD, describes a phase III trial conducted by the Gynecologic Oncology Group exploring treatment with bevacizumab for patients with recurrent cervical cancer.

Volker Heinemann, MD, PhD, professor, medical oncology, University of Munich in Munich, Germany, discusses the design and results from the FIRE-3 trial at the 2013 ASCO Annual Meeting.

Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the use of selumetinib in patients with advanced uveal melanoma.

Andrew D. Seidman, MD, comments on the findings of the phase III S0221 trial, which compared two schedules of paclitaxel as adjuvant therapy for breast cancer.

Electra D. Paskett, PhD, Professor, College of Medicine, The Ohio State University, describes the use of vinegar (acetic acid) as a cervical cancer screening tool.

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, comments on the impact of the approval of radium-223 for bone metastases from prostate cancer.

Lynn M. Schuchter, MD, Chief, Hematology Oncology, Department of Medicine, University of Pennsylvania, gives an overview of the treatment of advanced melanoma at the 2013 ASCO Annual Meeting.

Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, comments on the use of biomarkers in prostate cancer clinical trials.

Mark D. Pegram, MD, describes research into the antibody-drug conjugate T-DM1 (trastuzumab emtansine), following its FDA approval in February as a treatment for HER2-positive metastatic breast cancer.

Francesco Lo-Coco, MD, Hematology, University Tor Vergata, speaks at the 2012 American Society of Hematology annual meeting about the use of arsenic trioxide in acute promyelocytic leukemia.

George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses the mechanisms of resistance in breast cancer.

Robert Dreicer, MD, MS, chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute and professor of Medicine at the Cleveland Clinic in Ohio, discusses the treatment of bladder cancer.

Philip L. McCarthy, MD, Director, Blood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, comments on the move from doublet therapy to triplet therapy for multiple myeloma.

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses assays and intrinsic subtypes of breast cancer.

Fabrice Andre, MD, PhD, says that there are no targets in triple-negative breast cancer in accordance with the current vision of the disease.

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for patients with high-risk smoldering myeloma.

Eric J. Sherman, MD, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, comments on the use of cabozantinib and vandetinib in medullary thyroid cancer.

Michael J. Morris, MD, discusses an ongoing phase I/IIa study looking at radium-223 with docetaxel in patients with bone metastasis from castration-resistant prostate cancer.

Debu Tripathy, MD, Co-Leader, Women's Cancer Program, Norris Comprehensive Cancer Center, University of Southern California, describes intratumoral heterogeneity in patients with breast cancer.